key: cord-0824235-ab6m26pl authors: Meziyerh, Soufian; Zwart, Tom C.; van Etten, Ronald W.; Janson, Jeroen A.; van Gelder, Teun; Alwayn, Ian P. J.; de Fijter, Johan W.; Reinders, Marlies E. J.; Moes, Dirk J. A. R.; de Vries, Aiko P. J. title: Severe COVID‐19 in a renal transplant recipient: A focus on pharmacokinetics date: 2020-05-13 journal: Am J Transplant DOI: 10.1111/ajt.15943 sha: 56e65e6ffd5047c878d4077e147474cb257e3a9b doc_id: 824235 cord_uid: ab6m26pl The current coronavirus disease 2019 (COVID‐19) pandemic requires extra attention for immunocompromised patients, including solid organ transplant recipients. We report on a case of a 35‐year‐old renal transplant recipient who suffered from a severe COVID‐19 pneumonia. The clinical course was complicated by extreme overexposure to the mammalian target of rapamycin inhibitor everolimus, following coadministration of chloroquine and lopinavir/ritonavir therapy. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence‐based COVID‐19 therapy and concurrent pressure for exploration of experimental pharmacological treatment options. However, the risk‐benefit balance of experimental or off‐label therapy may be weighed differently in organ transplant recipients than in otherwise healthy COVID‐19 patients, owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy. With this case report, we aimed to achieve increased awareness and improved management of drug‐drug interactions associated with the various treatment options for COVID‐19 in renal transplant patients. This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2020 The Authors. American Journal of Transplantation published by Wiley Periodicals LLC on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons viruses, and adenoviruses suggested poor outcome. 1 Contrarily, this was not seen for Middle East respiratory syndrome (MERS). 2 It is currently unknown whether renal transplant recipients have increased susceptibility to develop complications of COVID-19 as compared to nontransplanted patients with end-stage renal disease. Previous reports suggested that immunosuppression might diminish the "immune system overdrive" underlying the development of acute respiratory distress syndrome (ARDS) and subsequent mortality. 3 Moreover, some immunosuppressants are hypothesized to have antiviral properties. Cyclosporine has shown in vitro antiviral potency against SARS-CoV-1 via cyclophilin inhibition, 4 whereas mycophenolate and mammalian target of rapamycin inhibitors (mTORis) may affect MERS-CoV (in vitro and in vivo) and SARS-CoV-1 (in vitro). 2 The exact biological mechanisms are, however, unknown. Currently, no evidence-based treatment for COVID-19 is available, with recommendations merely supported by in vitro studies. The Dutch Center for Disease Control and Prevention (Rijksinstituut voor Volksgezondheid en Milieu; RIVM) suggested initially chloroquine and lopinavir/ritonavir as an option for hospitalized patients based on the MERS and SARS-CoV-1 outbreaks. [5] [6] [7] Given the current pressure for experimental treatment for COVID-19, potential drug-drug interactions may befall organ transplant recipients using immunosuppression. We report on a renal transplant recipient with highly elevated everolimus concentrations after initiation of chloroquine and lopinavir/ritonavir for COVID-19 pneumonia. The main goal of this case report is to raise awareness for pharmacokinetic interactions between experimental COVID-19 therapy and maintenance immunosuppression in this particularly vulnerable population. The patient is a 35-year-old male with a medical history of end-stage renal disease of unknown origin. He underwent living-related renal transplantation in 2016. Immunosuppressive therapy was initiated according to the Triton study protocol (NCT02057965), which included subcutaneous alemtuzumab induction (15 mg QD on 2 consecutive days) and autologous mesenchymal stromal cells. Since transplantation, he has been receiving dual maintenance immunosuppressive therapy with everolimus (3 mg BID) and prednisolone acute respiratory alkalosis with hypoxemia, and a high anion gap metabolic acidosis due to renal insufficiency. Chest radiography showed peripheral consolidations in multiple lobes in the lung, highly suspicious for COVID-19 pneumonia (Figure 2A ). Nasopharyngeal swab for SARS-CoV-2 was positive, as was a urine pneumococcal antigen test. Details are summarized in Table 1 . Strict viral isolation followed, oxygen was given by nasal cannula and intravenous cefuroxime was started. Nonetheless, he was persistently dys-and tachypneic, resulting in admittance to the intensive care unit (ICU). He remained respiratory stable with 5 L of oxygen therapy through nasal cannula. Directly after assessing his QT c time, oral chloroquine (300 mg BID after 600 mg loading dose) and combination antiviral therapy This awareness can assist physicians in their decision-making during the current pandemic. However, more experience is required to enable evidence-based, efficacious, and safe COVID-19 care in renal transplant recipients. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. Data sharing is not applicable to this article as no new data were created or analyzed in this study. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia Coronaviruses and immunosuppressed patients. The facts during the third epidemic Cyclosporin A inhibits the replication of diverse coronaviruses Screening of an FDAapproved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture SARS: systematic review of treatment effects Drug treatment options for hospitalized patients with COVID-19 Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19 Clinical characteristics of coronavirus disease 2019 in China Renin-angiotensinaldosterone system inhibitors in patients with Covid-19 The novel coronavirus 2019 epidemic and kidneys A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review Drug interaction of chloroquine with ciclosporin Interaction between cyclosporin and chloroquine Cardiotoxicity of antimalarial drugs Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics